BIOMAT Database Logo BIOMAT Database Logo

Effects of OKY-046 and nifedipine in cyclosporine-induced renal dysfunction in rats. 1996

N Papanikolaou, and I Darlametsos, and G Tsipas, and P Morphake, and S Bokas, and G Gkikas, and A Hornych, and J Bariety, and E L Gkika, and I Karageorgou, and K Patsialos
Centre Franco-Hellenique de Recherches Biomedicales, Hôpital Général d'Agrinion, Greece.

Cyclosporine (CsA) (37.4 mumol/kg per day for 7 days) treated female Wistar rats exhibited significantly decreased creatinine clearance (Ccr) and body weight loss (BWL), but had neither proteinuria (PU) nor alteration in their urine volume (V). Light microscopic (LM) sections of rat kidneys showed that all kidneys were affected by lesions, mainly diffuse vacuolization. These changes were associated with decreased urinary excretion ratios of 6-ketoprostaglandin F1 alpha to thromboxane B2 (6kPGF1 alpha/TXB2) and prostaglandin E2 to TXB2 (PGE2/TXB2). When OKY-046, a TXA2-synthetase inhibitor or nifedipine (NFD), a calcium channel blocker and an antagonist of endotheline (ET), were administered in addition to CsA, they restored Ccr and increased urine V but they did not prevent BWL. LM sections showed that only 5 or 7 out of 9 kidneys of animals were affected, respectively. These changes were associated with prevention of the diminished ratios of urinary PGE2/TXB2 and 6kPGF1 alpha/TXB2 mainly in the OKY-046 treated animals. In conclusion, our results suggest that inhibitors of TXA2 or antagonists and/or inhibitors of endothelin play a protective role in the development of the dysfunction induced by CsA. However, the protection observed using OKY-046 and NFD did not reach that obtained by evening primrose oil (EPO) or Ketanserine (KTS), substances which prevented the fall of Ccr and BWL. Furthermore, with these protective agents only 5 out of 9 kidneys were affected and the lesions were of minor importance.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D007650 Ketanserin A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients. 3-(2-(4-(4-Fluorobenzoyl)piperidinol)ethyl)-2,4(1H,3H)-quinazolinedione,R-41,468,R-41468,R 41,468,R 41468,R41,468,R41468
D007677 Kidney Function Tests Laboratory tests used to evaluate how well the kidneys are working through examination of blood and urine. Function Test, Kidney,Function Tests, Kidney,Kidney Function Test,Test, Kidney Function,Tests, Kidney Function
D007684 Kidney Tubules Long convoluted tubules in the nephrons. They collect filtrate from blood passing through the KIDNEY GLOMERULUS and process this filtrate into URINE. Each renal tubule consists of a BOWMAN CAPSULE; PROXIMAL KIDNEY TUBULE; LOOP OF HENLE; DISTAL KIDNEY TUBULE; and KIDNEY COLLECTING DUCT leading to the central cavity of the kidney (KIDNEY PELVIS) that connects to the URETER. Kidney Tubule,Tubule, Kidney,Tubules, Kidney
D008041 Linoleic Acids Eighteen-carbon essential fatty acids that contain two double bonds. Acids, Linoleic
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D008689 Methacrylates Acrylic acids or acrylates which are substituted in the C-2 position with a methyl group. Methacrylate
D009543 Nifedipine A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure. Adalat,BAY-a-1040,Bay-1040,Cordipin,Cordipine,Corinfar,Fenigidin,Korinfar,Nifangin,Nifedipine Monohydrochloride,Nifedipine-GTIS,Procardia,Procardia XL,Vascard,BAY a 1040,BAYa1040,Bay 1040,Bay1040,Monohydrochloride, Nifedipine,Nifedipine GTIS
D010938 Plant Oils Oils derived from plants or plant products. Oils, Plant,Oils, Vegetable,Plant Oil,Vegetable Oil,Vegetable Oils,Oil, Plant,Oil, Vegetable
D002121 Calcium Channel Blockers A class of drugs that act by selective inhibition of calcium influx through cellular membranes. Calcium Antagonists, Exogenous,Calcium Blockaders, Exogenous,Calcium Channel Antagonist,Calcium Channel Blocker,Calcium Channel Blocking Drug,Calcium Inhibitors, Exogenous,Channel Blockers, Calcium,Exogenous Calcium Blockader,Exogenous Calcium Inhibitor,Calcium Channel Antagonists,Calcium Channel Blocking Drugs,Exogenous Calcium Antagonists,Exogenous Calcium Blockaders,Exogenous Calcium Inhibitors,Antagonist, Calcium Channel,Antagonists, Calcium Channel,Antagonists, Exogenous Calcium,Blockader, Exogenous Calcium,Blocker, Calcium Channel,Blockers, Calcium Channel,Calcium Blockader, Exogenous,Calcium Inhibitor, Exogenous,Channel Antagonist, Calcium,Channel Blocker, Calcium,Inhibitor, Exogenous Calcium

Related Publications

N Papanikolaou, and I Darlametsos, and G Tsipas, and P Morphake, and S Bokas, and G Gkikas, and A Hornych, and J Bariety, and E L Gkika, and I Karageorgou, and K Patsialos
Effects of tetrodotoxin and OKY-046 in renal ischemia reperfusion.
August 1999, The Journal of surgical research,
N Papanikolaou, and I Darlametsos, and G Tsipas, and P Morphake, and S Bokas, and G Gkikas, and A Hornych, and J Bariety, and E L Gkika, and I Karageorgou, and K Patsialos
Renal effects of the inhibitor of thromboxane A2-synthetase OKY-046.
June 1986, Experientia,
N Papanikolaou, and I Darlametsos, and G Tsipas, and P Morphake, and S Bokas, and G Gkikas, and A Hornych, and J Bariety, and E L Gkika, and I Karageorgou, and K Patsialos
Effects of thromboxane A2 synthesis inhibitor (OKY-046) on total liver ischemia in rats.
January 1996, International surgery,
N Papanikolaou, and I Darlametsos, and G Tsipas, and P Morphake, and S Bokas, and G Gkikas, and A Hornych, and J Bariety, and E L Gkika, and I Karageorgou, and K Patsialos
Effects of thromboxane synthetase inhibitor (OKY-046) on urinary prostaglandin excretion and renal function in streptozotocin-induced diabetic rat.
January 1994, Journal of diabetes and its complications,
N Papanikolaou, and I Darlametsos, and G Tsipas, and P Morphake, and S Bokas, and G Gkikas, and A Hornych, and J Bariety, and E L Gkika, and I Karageorgou, and K Patsialos
Pulmonary vascular response to thrombin: effects of thromboxane synthetase inhibition with OKY-046 and OKY-1581.
December 1984, Prostaglandins,
N Papanikolaou, and I Darlametsos, and G Tsipas, and P Morphake, and S Bokas, and G Gkikas, and A Hornych, and J Bariety, and E L Gkika, and I Karageorgou, and K Patsialos
Inhibitory effects of OKY-046 on spasmogen-induced bronchoconstrictions in sensitized and non-sensitized guinea pigs.
February 1990, Japanese journal of pharmacology,
N Papanikolaou, and I Darlametsos, and G Tsipas, and P Morphake, and S Bokas, and G Gkikas, and A Hornych, and J Bariety, and E L Gkika, and I Karageorgou, and K Patsialos
Effect of thromboxane synthetase inhibitors (OKY-046, OKY-1580) on experimentally induced air embolism in anesthetized dogs.
February 1986, Prostaglandins, leukotrienes, and medicine,
N Papanikolaou, and I Darlametsos, and G Tsipas, and P Morphake, and S Bokas, and G Gkikas, and A Hornych, and J Bariety, and E L Gkika, and I Karageorgou, and K Patsialos
[Effect of OKY-046 on airway hyperresponsiveness induced by ozone in dogs].
May 1990, Nihon yakurigaku zasshi. Folia pharmacologica Japonica,
N Papanikolaou, and I Darlametsos, and G Tsipas, and P Morphake, and S Bokas, and G Gkikas, and A Hornych, and J Bariety, and E L Gkika, and I Karageorgou, and K Patsialos
Cyclosporine-induced renal dysfunction.
March 2004, Transplantation proceedings,
N Papanikolaou, and I Darlametsos, and G Tsipas, and P Morphake, and S Bokas, and G Gkikas, and A Hornych, and J Bariety, and E L Gkika, and I Karageorgou, and K Patsialos
[Effects of OKY 046 on responses to norepinephrine in rat mesenteric arterioles].
March 1986, Masui. The Japanese journal of anesthesiology,
Copied contents to your clipboard!